Dr. Winkelman joined Poseida in October 2019 as vice president, intellectual property. Dr. Winkelman brings a wide range of experience that will be important to maximize the value of Poseida’s gene engineering technologies. He was previously executive director, intellectual property at Mirati Therapeutics, Inc. and has served in senior management positions, including vice president, intellectual property at BioSante Pharmaceuticals, Cell Genesys Inc. and Elitra Pharmaceuticals. Dr Winkelman received a J.D. from the University of San Diego, a Ph.D. from the University of California, Irvine and an M.A. and B.A. from Southern Illinois University.